GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Phoenix Biotech Acquisition Corp (NAS:PBAX) » Definitions » Market Cap

Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) Market Cap : $36.47 Mil (As of Jun. 08, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Phoenix Biotech Acquisition Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Phoenix Biotech Acquisition's share price for the quarter that ended in Sep. 2023 was $10.86. Phoenix Biotech Acquisition's Shares Outstanding (EOP) for the quarter that ended in Sep. 2023 was 6.25 Mil. Therefore, Phoenix Biotech Acquisition's market cap for the quarter that ended in Sep. 2023 was $67.83 Mil.

Phoenix Biotech Acquisition's quarterly market cap increased from Mar. 2023 ($72.30 Mil) to Jun. 2023 ($73.79 Mil) but then declined from Jun. 2023 ($73.79 Mil) to Sep. 2023 ($67.83 Mil).

Phoenix Biotech Acquisition's annual market cap increased from . 20 ($0.00 Mil) to Dec. 2021 ($227.74 Mil) but then declined from Dec. 2021 ($227.74 Mil) to Dec. 2022 ($69.53 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Phoenix Biotech Acquisition's Enterprise Value for Today is $37.75 Mil.


Phoenix Biotech Acquisition Market Cap Historical Data

The historical data trend for Phoenix Biotech Acquisition's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phoenix Biotech Acquisition Market Cap Chart

Phoenix Biotech Acquisition Annual Data
Trend Dec21 Dec22
Market Cap
227.74 69.53

Phoenix Biotech Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only 231.88 69.53 72.30 73.79 67.83

Competitive Comparison of Phoenix Biotech Acquisition's Market Cap

For the Shell Companies subindustry, Phoenix Biotech Acquisition's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phoenix Biotech Acquisition's Market Cap Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Phoenix Biotech Acquisition's Market Cap distribution charts can be found below:

* The bar in red indicates where Phoenix Biotech Acquisition's Market Cap falls into.



Phoenix Biotech Acquisition Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Phoenix Biotech Acquisition's Market Cap for the fiscal year that ended in Dec. 2022 is calculated as

Market Cap (A: Dec. 2022 )=Share Price (A: Dec. 2022 )*Shares Outstanding (EOP) (A: Dec. 2022 )
=$10.2703*6.76955
=$69.53

Phoenix Biotech Acquisition's Market Cap for the quarter that ended in Sep. 2023 is calculated as

Market Cap (Q: Sep. 2023 )=Share Price (Q: Sep. 2023 )*Shares Outstanding (EOP) (Q: Sep. 2023 )
=$10.86*6.24621
=$67.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Phoenix Biotech Acquisition  (NAS:PBAX) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Phoenix Biotech Acquisition Market Cap Related Terms

Thank you for viewing the detailed overview of Phoenix Biotech Acquisition's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Phoenix Biotech Acquisition (Phoenix Biotech Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
2201 Broadway, Suite 705, Oakland, CA, USA, 94612
Website
Phoenix Biotech Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company intends to pursue an acquisition opportunity in any business, industry, sector or geographical location, industries that complement management team's background, and to capitalize on the ability of management team to identify and acquire a business in the healthcare or healthcare related industries in the United States and Europe.
Executives
Caroline M Loewy director 300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Brian G Atwood director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Kathleen Laporte director
Christopher B Ehrlich director, 10 percent owner, officer: CEO and and Secretary 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Douglas Fisher officer: President 587 PATROL RD, WOODSIDE CA 94062
Daniel E. Geffken officer: Chief Financial Officer DAMONMILL SQUARE, SUITE 6A, CONCORD MA 01742
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Phoenix Biotech Sponsor, Llc 10 percent owner 2001 MARKET STREET, SUITE 3400, PHILADELPHIA PA 19103